Can aspirin resistance be clinically predicted in strorke patients?

被引:23
作者
Seok, Jung Im [2 ]
Joo, In Soo [3 ]
Yoon, Jung Han [3 ]
Choi, Yun Jung [3 ]
Lee, Phil Hyu [3 ]
Huh, Kyoon [3 ]
Bang, Oh Young [1 ]
机构
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Neurol,Stroke & Cerebrovasc Ctr,Gangnam Gu, Seoul 135710, South Korea
[2] Catholic Univ Daegu, Sch Med, Dept Neurol, Daegu, South Korea
[3] Ajou Univ Hosp, Dept Neurol, Suwon, South Korea
关键词
aspirin resistance; ischemic stroke; aspirin;
D O I
10.1016/j.clineuro.2007.09.005
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objectives: Aspirin resistance is one of several possible explanations for limited efficacy or treatment failure of aspirin. However, the predictors of aspirin resistance are not well known. We therefore conducted a study of laboratory-defined aspirin resistance in Korean patients with ischemic stroke and considered a wide range of factors as possible predictors. Patients and methods: A total of 88 patients taking aspirin daily for the secondary prevention of stroke were included. Platelet function was assessed using the Rapid Platelet Function Assay-Aspirin (RPFA-ASA) system and the level of urinary thromboxane B2 (TX-B2). The result of the RPFA-ASA system was expressed as an aspirin reaction unit (ARU). We analyzed a wide range of factors including demographic data, stroke risk factors, and laboratory findings to identify the clinical predictors of aspirin resistance. Results: Eleven (12%) patients were identified as aspirin resistant by the ARU criteria. Univariate analysis showed that an older age, lower LDL cholesterol levels, and concurrent use of angiotensin converting enzyme inhibitors or receptor blockers were related to aspirin resistance by ARU criteria. Aspirin resistance by urinary TX-B2 criteria was observed in 18 (25%) patients and associated with an older age, metabolic syndrome, diabetes, cigarette smoking, and the use of angiotensin-converting enzyme inhibitors or receptor blockers. In multivariate analysis, this association lost significance by ARU criteria, and only lower fibrinogen levels were associated with increased risk by TX-B2 criteria. In addition, the stroke subtypes and the degree of atherosclerosis were not associated with aspirin resistance. The correlation between the two criteria was poor (r = -0.115, p = 0.34). Conclusion: Despite the comprehensive analysis of this study, we failed to identify independent predictors for laboratory-defined aspirin resistance. Additionally, little overlap was found between the two criteria with which to assess aspirin resistance. (C) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:110 / 116
页数:7
相关论文
共 31 条
[1]   CLASSIFICATION OF SUBTYPE OF ACUTE ISCHEMIC STROKE - DEFINITIONS FOR USE IN A MULTICENTER CLINICAL-TRIAL [J].
ADAMS, HP ;
BENDIXEN, BH ;
KAPPELLE, LJ ;
BILLER, J ;
LOVE, BB ;
GORDON, DL ;
MARSH, EE ;
KASE, CS ;
WOLF, PA ;
BABIKIAN, VL ;
LICATAGEHR, EE ;
ALLEN, N ;
BRASS, LM ;
FAYAD, PB ;
PAVALKIS, FJ ;
WEINBERGER, JM ;
TUHRIM, S ;
RUDOLPH, SH ;
HOROWITZ, DR ;
BITTON, A ;
MOHR, JP ;
SACCO, RL ;
CLAVIJO, M ;
ROSENBAUM, DM ;
SPARR, SA ;
KATZ, P ;
KLONOWSKI, E ;
CULEBRAS, A ;
CAREY, G ;
MARTIR, NI ;
FICARRA, C ;
HOGAN, EL ;
CARTER, T ;
GURECKI, P ;
MUNTZ, BK ;
RAMIREZLASSEPAS, M ;
TULLOCH, JW ;
QUINONES, MR ;
MENDEZ, M ;
ZHANG, SM ;
ALA, T ;
JOHNSTON, KC ;
ANDERSON, DC ;
TARREL, RM ;
NANCE, MA ;
BUDLIE, SR ;
DIERICH, M ;
HELGASON, CM ;
HIER, DB ;
SHAPIRO, RA .
STROKE, 1993, 24 (01) :35-41
[2]   Antiplatelet effect of aspirin in patients with cerebrovascular disease [J].
Alberts, MJ ;
Bergman, DL ;
Molner, E ;
Jovanovic, BD ;
Ushiwata, I ;
Teruya, J .
STROKE, 2004, 35 (01) :175-178
[3]  
[Anonymous], 1998, JAMA, V279, P1265
[4]  
Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71
[5]   Inflammatory markers, rather than conventional risk factors, are different between carotid and MCA atherosclerosis [J].
Bang, OY ;
Lee, PH ;
Yoon, SR ;
Lee, MA ;
Joo, IS ;
Huh, K .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2005, 76 (08) :1128-1134
[6]   Association of the metabolic syndrome with intracranial atherosclerotic stroke [J].
Bang, OY ;
Kim, JW ;
Lee, JH ;
Lee, MA ;
Lee, PH ;
Joo, IS ;
Huh, K .
NEUROLOGY, 2005, 65 (02) :296-298
[7]   Aspirin resistance in secondary stroke prevention [J].
Berrouschot, J ;
Schwetlick, B ;
von Twickel, G ;
Fischer, C ;
Uhlemann, H ;
Siegemund, T ;
Siegemund, A ;
Roessler, A .
ACTA NEUROLOGICA SCANDINAVICA, 2006, 113 (01) :31-35
[8]  
Coleman J, 2004, POINT CARE, V3, P77, DOI DOI 10.1097/01.P0C.0000127153.41926.BA
[9]   Prevalence of aspirin resistance measured by PFA-100 [J].
Coma-Canella, I ;
Velasco, A ;
Castano, S .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2005, 101 (01) :71-76
[10]   Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events [J].
Eikelboom, JW ;
Hirsh, J ;
Weitz, JI ;
Johnston, M ;
Yi, Q ;
Yusuf, S .
CIRCULATION, 2002, 105 (14) :1650-1655